Skip to main content

Table 1 Adverse events of interest

From: One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

AE category

Physician-reported AEs included in the analysis

SIEs

Infections for which the patient was hospitalized and/or received intravenous antibiotics, which were categorized as follows: joint/bursa, cellulitis/skin, sinusitis, diverticulitis, sepsis, pneumonia, bronchitis, gastroenteritis, meningitis/encephalitis, urinary tract infection, upper respiratory infection, active tuberculosis (latent tuberculosis infection was not included), and other infections

SIE microorganism

Opportunistic infections: coccidioidomycosis, Cryptococcus, herpes zoster, histoplasmosis, John Cunningham virus, Listeria, Pneumocystis, active tuberculosis (latent tuberculosis infection was not included), and other opportunistic infections. Nonopportunistic infections: methicillin-resistant Staphylococcus aureus (MRSA), bacterial infection other than MRSA, and other nonopportunistic infections

Malignancies

Nonmelanoma skin cancer, melanoma skin cancer, lymphoma, breast cancer, lung cancer, and other cancers

CVEs

Myocardial infarction, transient ischemic attack, stroke, congestive heart failure with hospitalization, cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, acute coronary syndrome, unstable angina, hypertension with hospitalization, peripheral arterial thromboembolic event, urgent peripheral arterial revascularization, peripheral ischemia or gangrene (necrosis), and other CVEs

  1. Abbreviations: AE Adverse event, SIE Serious infection event, CVE Cardiovascular event